Please use this identifier to cite or link to this item:
https://dora.health.qld.gov.au/qldresearchjspui/handle/1/504
Title: | Surgery for Crohn's disease and anti-TNF agents: the changing scenario | Authors: | Van Den Bogaerde, J. Sorrentino, D. Fogel, S. |
Issue Date: | 2013 | Source: | 7, (8), 2013, p. 689-700 | Pages: | 689-700 | Journal: | Expert Review of Gastroenterology and Hepatology | Abstract: | Surgery has been a mainstay of therapy for Crohn's disease for a long time, essentially as a consequence of the fairly modest efficacy of traditional medications such as immunomodulators, antibiotics and 5-ASA, especially in severe cases. However, in the past decade and half, the advent of anti-TNF agents has greatly changed the medical approach to this disease and may modify its general management as well. Here, we have reviewed the current literature on incidence of surgery, timing of surgery and postoperative recurrence of Crohn's disease before and after the advent of anti-TNF agents. In addition, we have reviewed the risk of perioperative complications in patients on anti-TNF agents before surgery. The data show that the use of these medications is changing or expecting to change shortly a number of surgical aspects of Crohn's disease management. 2013 Informa UK Ltd. | DOI: | http://dx.doi.org/10.1586/17474124.2013.842895 | Resources: | http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed11&AN=2013708296 | Keywords: | anti-TNF agentsCrohn's disease;incidence of surgery;infliximab;perioperative complications;postoperative recurrence;timing of surgery;antibody titer;clinical effectiveness;Crohn disease/dt [Drug Therapy];Crohn disease/su [Surgery];disease association;disease control;disease severity;dose response;drug efficacy;drug safety;drug tolerability;history of medicine;human;incidence;intestine surgery;laparoscopy;low drug dose;outcome assessment;patient assessment;patient safety;peroperative complication/co [Complication];postoperative complication/co [Complication];premedication;recurrent disease/co [Complication];review;risk assessment;risk factor;surgical infection/co [Complication];unspecified side effect/si [Side Effect];adalimumab/ct [Clinical Trial];adalimumab/dt [Drug Therapy];certolizumab/dt [Drug Therapy];infliximab/ae [Adverse Drug Reaction];infliximab/ct [Clinical Trial];infliximab/cm [Drug Comparison];infliximab/dt [Drug Therapy];mesalazine/cm [Drug Comparison];mesalazine/dt [Drug Therapy];mesalazine/po [Oral Drug Administration];methotrexate/cm [Drug Comparison];methotrexate/do [Drug Dose];methotrexate/dt [Drug Therapy];methotrexate/po [Oral Drug Administration];monoclonal antibody/dt [Drug Therapy];placebo;tumor necrosis factor alpha antibody/dt [Drug Therapy];unclassified drug | Type: | Article |
Appears in Sites: | Sunshine Coast HHS Publications |
Show full item record
Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.